Relacorilant

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Hypercortisolism

Conditions

Hypercortisolism

Trial Timeline

Jul 27, 2020 → Sep 19, 2024

NCT ID

NCT04308590

About Relacorilant

Relacorilant is a phase 3 stage product being developed by Corcept Therapeutics for Hypercortisolism. The current trial status is completed. This product is registered under clinical trial identifier NCT04308590. Target conditions include Hypercortisolism.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04308590	Phase 3	Completed	Jul 27, 2020	Sep 19, 2024	Hypercortisolism
NCT06094725	Phase 1	Completed	Jan 6, 2020	Dec 14, 2020	Hepatic Impairment
NCT03697109	Phase 3	Completed	Nov 15, 2018	Apr 15, 2024	Cushing Syndrome
NCT03604198	Phase 2	Active	May 7, 2018	Dec 1, 2026	Cushing Syndrome

Competing Products

1 competing product in Hypercortisolism

See all competitors

Product	Company	Stage	Hype Score
Mifepristone 300 MG [Korlym] + Placebo for mifepristone	Corcept Therapeutics	Approved	80

Other Products from Corcept Therapeutics

Mifepristone 300 MG [Korlym] + Placebo for mifepristoneApproved

mifepristonePhase 3

mifepristone + placeboPhase 3

Mifepristone + placeboPhase 3

RelacorilantPhase 3